Bessemer Group
CGTX icon

Bessemer Group’s Cognition Therapeutics CGTX Stock Holding History

Bessemer Group’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,797
Closed -$19K – 2514
2025
Q4 		$19K Hold
13,797
– – ﹤0.01% 1890
2025
Q3 		$19K Hold
13,797
– – ﹤0.01% 1704
2025
Q2 		$4K Hold
13,797
– – ﹤0.01% 2060
2025
Q1 		$6K Hold
13,797
– – ﹤0.01% 1943
2024
Q4 		$10K Hold
13,797
– – ﹤0.01% 1754
2024
Q3 		$6K Buy
+13,797
New +$14.2K ﹤0.01% 1838

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Bessemer Group's CGTX Position: Q1 2026 in Review

Bessemer Group sold out of Cognition Therapeutics (CGTX) in Q1 2026, closing a stake of 13,797 shares — an estimated $19K sold.

Bessemer Group first reported a position in CGTX in Q3 2024 and held it in 6 quarters. The position peaked at $19K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Bessemer Group reported no remaining Cognition Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bessemer Group sold 13,797 Cognition Therapeutics shares in Q1 2026, an estimated $19K.
  • Bessemer Group first reported a position in Cognition Therapeutics in Q3 2024 and held it in 6 quarters.
  • Bessemer Group's Cognition Therapeutics position peaked at $19K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.